Compare ATRC & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATRC | KBDC |
|---|---|---|
| Founded | 2000 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.1B |
| IPO Year | 2005 | N/A |
| Metric | ATRC | KBDC |
|---|---|---|
| Price | $40.86 | $15.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $52.22 | $15.80 |
| AVG Volume (30 Days) | ★ 575.0K | 394.3K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 12.50% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $518,304,999.00 | N/A |
| Revenue This Year | $16.90 | $193.84 |
| Revenue Next Year | $12.29 | $9.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.80 | N/A |
| 52 Week Low | $28.29 | $13.06 |
| 52 Week High | $43.11 | $17.99 |
| Indicator | ATRC | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 62.89 | 50.62 |
| Support Level | $38.92 | $15.26 |
| Resistance Level | $42.60 | $15.55 |
| Average True Range (ATR) | 1.53 | 0.28 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 80.06 | 10.98 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.